Johnson & Johnson Innovation: collaboration for innovation in healthcare

[ad_1]

At the end of May, Johnson & Johnson Innovation set out to meet the innovation ecosystem in France with the event: “Meet With Johnson & Johnson Innovation in France”. Return on this event rich in exchanges.

Today, Johnson & Johnson Innovation is present throughout the world and offers different types of structures to bring out innovative solutions and collaborations with players in healthcare innovation. Johnson & Johnson Innovation aims to meet its industrial needs and those of innovative entrepreneurs.

To meet the health innovation ecosystem in France, Johnson & Johnson Innovation organized a virtual event on May 26 and 27: “Meet With Johnson & Johnson Innovation in France”.

Throughout the afternoon of May 26 and the day of May 27, Johnson & Johnson Innovation offered meetings between players in the French health ecosystem and its experts to identify potential collaborations and projects.

As an introduction to this event a webconference was organized to present Johnson & Johnson Innovation, its organization, its projects and the benefits of collaboration.

During this event, Siau Bai, in charge of France at Johnson & Johnson Innovation, presented the different entities and the main interlocutors of this innovation structure.

To make the link with the innovation ecosystem in France, Emmanuelle Quiles, President of Janssen France, presented the group through its three activities: Pharmaceuticals (Janssen which she heads in France), Medical devices and Consumer Health. Very involved within Janssen in the deployment of technological solutions in the service of health such as artificial intelligence, she indicated that opening up to the innovation ecosystem is now essential for a pharmaceutical player: ” partnerships with the innovation ecosystem are absolutely essential for the future of healthcare “.

She notably indicated that she wanted to engage Janssen France in the desire to make France one of the leaders in artificial intelligence by recalling a certain number of partnerships carried out with AIforHealth, Ad Scientam, Heva or the Health Data Hub.

Nerida Scott, who heads Johnson & Johnson Innovation’s EMEA Innovation Center, then presented the different structures deployed to bring out innovative solutions and collaborations with healthcare innovation players:

• Innovation Centers (Early Stage Acceleration): 4 innovation centers are present on 3 continents to create connections with innovation ecosystems all over the planet. More than 580 partnerships have been concluded over the past 6 years.

• JJDC (Strategic Investors): investment fund to support the development of innovative companies

• JLABS (Life Science Incubators): 13 incubation sites around the world with more than 700 companies supported

• Business Development : Focuses on mid-stage and late-stage collaborations with established pharmaceutical, medical device and consumer health companies to accelerate disruptive innovations to address unmet medical needs and create real value in businesses. Johnson & Johnson priority areas: acquisition of assets, businesses and technologies, or entering into strategic collaborations, licenses and business partnerships.

To provide concrete feedback, several French players who have collaborated with Johnson & Johnson Innovation have provided their testimonials. This is the case of Lars Rogge from the Institut Pasteur who shared his experience of collaboration within the framework of a research program recently signed with Janssen and the APHP to explore the signaling pathways involved in chronic inflammatory diseases in rheumatology.

Luc Soler, president of Visible Patient, a Strasbourg startup specializing in 3D medical images for surgery, also participated in his experience. ” Collaborating with Johnson & Johnson Innovation contacts is very easy because they want to move projects forward, and are fighting for that. They believe in the project so that is really a great experience of common trust and working together. “.

For his part, Jacques Husser, co-founder and director of Remedee Labs, a startup to improve the lives of people with chronic pain using the first endorphins stimulator associated with a digital services platform, reviewed his experience. incubation within JLABS. ” This incubation allowed us to be put in touch with JLABS operational partners, to get in touch with investors, to participate in webinars and to meet other startups to share experiences.. “

Launch of a new call for applications!

To continue the relationship with the innovation ecosystem in France, Johnson & Johnson Innovation is launching a new application as part of this “Meet with Johnson & Johnson Innovation in France” program.

Health players, innovators, start-ups… take part in this collaboration opportunity by responding to this new call for applications. Register by July 5, 2021 here>

Johnson & Johnson Innovation is looking for partnerships in certain priority areas but if you offer a disruptive solution in an area not listed, you are encouraged to participate:

• Pharmaceuticals: Cardiovascular, Metabolism & Retinal, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, Pulmonary Hypertension, Platforms

• Medical Devices: 3D Printing, Cardiovascular, Contact Lens, Infection Prevention, Neurovascular, Obesity, Osteoarthritis, Robotic Surgery and Digital Solutions, Surgical Oncology, Vision Surgery

• Consumer Health: Self Care, Skin Health

• Cross-Sector: Health Technology, Lung Cancer, Microbiome, Immunosciences, Predictive Analytics, Behavioral Science, Global Public Health

List of priority areas

For information, over the past 3 years no less than 8 collaborations with researchers and innovators have been set up in France by Johnson & Johnson Innovation.

You have until July 5 to register and meet the Johnson & Johnson Innovation experts

About Johnson & Johnson Innovation

Johnson & Johnson Innovation Ltd is focused on accelerating all stages of innovation around the world and building collaborations between entrepreneurs and Johnson & Johnson. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with unique access to science and technology experts who can facilitate collaborations between Johnson & Johnson’s pharmaceutical, medical device and consumer health companies.

Under the aegis of Johnson & Johnson Innovation, through our innovation centers, JLABS, JJDC and J&J teams around the world, we are in contact with startups, biotechs, private research institutes and audiences and academics in order to create personalized agreements and unprecedented collaborations that accelerate the development of innovations aimed at meeting the unmet needs of patients. For more information on Johnson & Johnson Innovation, we invite you to visit the website www.jnjinnovation.com.

Post produced in partnership with Johnson & Johnson Innovation

Similar articles

[ad_2]